肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Venclyxto（venetoclax）治疗慢性淋巴细胞性白血病：已获NICE支持

2020-11-11 Allan MedSci原创

venetoclax慢性淋巴细胞性白血病Venclyxto
关注

美国国立卫生研究院（NICE）建议将AbbVie的Venclyxto（venetoclax）用作慢性淋巴细胞性白血病（CLL）的常规治疗方法。

B细胞淋巴瘤2（BCL-2）可以抑制由多种细胞毒因素所引起的细胞死亡。BCL-2的过度表达能增强所观察细胞对大多数细胞毒素的抵抗性。这一发现使人们认识到凋亡的各种信号转导途径有一个共同的通路或交汇点，而该通路或交汇点受BCL-2调节。

NICE建议将AbbVie的Venclyxto（venetoclax）用作慢性淋巴细胞性白血病（CLL）的常规治疗方法。口服B细胞淋巴瘤2（BCL-2）抑制剂Venclyxto（venetoclax）已被证明与罗氏Gazyvaro（obinutuzumab）联用可用于尚未接受过治疗的CLL患者。

NICE已推荐Venclyxto联合Gazyvaro用于具有del（17p）/ TP53突变的CLL患者和没有del（17p）/ TP53突变的CLL患者，这些患者不适合使用环磷酰胺和利妥昔单抗（FCR）或苯达莫司汀和利妥昔单抗（BR）。除了这种适应症外，NICE还建议将Veclyxto组合疗法用于无del（17p）/ TP53突变且适用FCR或BR的患者。

III期CLL14试验证实，在未经治疗的CLL患者中，Venclyxto联合Gazyvaro组的三年PFS率估计值为81.9％，而接受常用化学免疫疗法苯丁酸氮芥-奥比纽妥单抗（ClbG）的患者的三年PFS率为49.5％。

 

原始出处：

http://www.pharmatimes.com/news/viivs_long-acting_hiv_drug_beats_standard_of_care_in_prevention_study_1356736

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1805194, encodeId=a14118051942d, content=<a href='/topic/show?id=3138e790655' target=_blank style='color:#2F92EE;'>#细胞性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77906, encryptionId=3138e790655, topicName=细胞性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=86b7385, createdName=lqrandywkz, createdTime=Wed Feb 10 08:48:28 CST 2021, time=2021-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734273, encodeId=dc531e3427390, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Jan 25 03:48:28 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715747, encodeId=7e191e1574717, content=<a href='/topic/show?id=c042183e4ad' target=_blank style='color:#2F92EE;'>#Venclyxto#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18374, encryptionId=c042183e4ad, topicName=Venclyxto)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=326b32021361, createdName=lifestar, createdTime=Mon Jan 25 13:48:28 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289094, encodeId=92e4128909463, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Fri Nov 13 13:48:28 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302348, encodeId=7b4113023486e, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Fri Nov 13 13:48:28 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391424, encodeId=e8af139142472, content=<a href='/topic/show?id=619a535491c' target=_blank style='color:#2F92EE;'>#慢性淋巴细胞性白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53549, encryptionId=619a535491c, topicName=慢性淋巴细胞性白血病)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epHkicC6GE1behbwHywld8qq5n70MWsL3lMUJYYzicic8Fh8tUgSDljeibIQrAeBicATBRXbcCRfFZGK6g/132, createdBy=1d8d2500080, createdName=ms5439512287675881, createdTime=Fri Nov 13 13:48:28 CST 2020, time=2020-11-13, status=1, ipAttribution=)]
    2021-02-10 lqrandywkz

    #细胞性#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1805194, encodeId=a14118051942d, content=<a href='/topic/show?id=3138e790655' target=_blank style='color:#2F92EE;'>#细胞性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77906, encryptionId=3138e790655, topicName=细胞性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=86b7385, createdName=lqrandywkz, createdTime=Wed Feb 10 08:48:28 CST 2021, time=2021-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734273, encodeId=dc531e3427390, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Jan 25 03:48:28 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715747, encodeId=7e191e1574717, content=<a href='/topic/show?id=c042183e4ad' target=_blank style='color:#2F92EE;'>#Venclyxto#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18374, encryptionId=c042183e4ad, topicName=Venclyxto)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=326b32021361, createdName=lifestar, createdTime=Mon Jan 25 13:48:28 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289094, encodeId=92e4128909463, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Fri Nov 13 13:48:28 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302348, encodeId=7b4113023486e, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Fri Nov 13 13:48:28 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391424, encodeId=e8af139142472, content=<a href='/topic/show?id=619a535491c' target=_blank style='color:#2F92EE;'>#慢性淋巴细胞性白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53549, encryptionId=619a535491c, topicName=慢性淋巴细胞性白血病)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epHkicC6GE1behbwHywld8qq5n70MWsL3lMUJYYzicic8Fh8tUgSDljeibIQrAeBicATBRXbcCRfFZGK6g/132, createdBy=1d8d2500080, createdName=ms5439512287675881, createdTime=Fri Nov 13 13:48:28 CST 2020, time=2020-11-13, status=1, ipAttribution=)]
    2021-01-25 canlab

    #NET#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1805194, encodeId=a14118051942d, content=<a href='/topic/show?id=3138e790655' target=_blank style='color:#2F92EE;'>#细胞性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77906, encryptionId=3138e790655, topicName=细胞性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=86b7385, createdName=lqrandywkz, createdTime=Wed Feb 10 08:48:28 CST 2021, time=2021-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734273, encodeId=dc531e3427390, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Jan 25 03:48:28 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715747, encodeId=7e191e1574717, content=<a href='/topic/show?id=c042183e4ad' target=_blank style='color:#2F92EE;'>#Venclyxto#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18374, encryptionId=c042183e4ad, topicName=Venclyxto)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=326b32021361, createdName=lifestar, createdTime=Mon Jan 25 13:48:28 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289094, encodeId=92e4128909463, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Fri Nov 13 13:48:28 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302348, encodeId=7b4113023486e, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Fri Nov 13 13:48:28 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391424, encodeId=e8af139142472, content=<a href='/topic/show?id=619a535491c' target=_blank style='color:#2F92EE;'>#慢性淋巴细胞性白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53549, encryptionId=619a535491c, topicName=慢性淋巴细胞性白血病)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epHkicC6GE1behbwHywld8qq5n70MWsL3lMUJYYzicic8Fh8tUgSDljeibIQrAeBicATBRXbcCRfFZGK6g/132, createdBy=1d8d2500080, createdName=ms5439512287675881, createdTime=Fri Nov 13 13:48:28 CST 2020, time=2020-11-13, status=1, ipAttribution=)]
    2021-01-25 lifestar

    #Venclyxto#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1805194, encodeId=a14118051942d, content=<a href='/topic/show?id=3138e790655' target=_blank style='color:#2F92EE;'>#细胞性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77906, encryptionId=3138e790655, topicName=细胞性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=86b7385, createdName=lqrandywkz, createdTime=Wed Feb 10 08:48:28 CST 2021, time=2021-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734273, encodeId=dc531e3427390, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Jan 25 03:48:28 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715747, encodeId=7e191e1574717, content=<a href='/topic/show?id=c042183e4ad' target=_blank style='color:#2F92EE;'>#Venclyxto#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18374, encryptionId=c042183e4ad, topicName=Venclyxto)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=326b32021361, createdName=lifestar, createdTime=Mon Jan 25 13:48:28 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289094, encodeId=92e4128909463, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Fri Nov 13 13:48:28 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302348, encodeId=7b4113023486e, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Fri Nov 13 13:48:28 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391424, encodeId=e8af139142472, content=<a href='/topic/show?id=619a535491c' target=_blank style='color:#2F92EE;'>#慢性淋巴细胞性白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53549, encryptionId=619a535491c, topicName=慢性淋巴细胞性白血病)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epHkicC6GE1behbwHywld8qq5n70MWsL3lMUJYYzicic8Fh8tUgSDljeibIQrAeBicATBRXbcCRfFZGK6g/132, createdBy=1d8d2500080, createdName=ms5439512287675881, createdTime=Fri Nov 13 13:48:28 CST 2020, time=2020-11-13, status=1, ipAttribution=)]
    2020-11-13 fusion

    #NICE#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1805194, encodeId=a14118051942d, content=<a href='/topic/show?id=3138e790655' target=_blank style='color:#2F92EE;'>#细胞性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77906, encryptionId=3138e790655, topicName=细胞性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=86b7385, createdName=lqrandywkz, createdTime=Wed Feb 10 08:48:28 CST 2021, time=2021-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734273, encodeId=dc531e3427390, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Jan 25 03:48:28 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715747, encodeId=7e191e1574717, content=<a href='/topic/show?id=c042183e4ad' target=_blank style='color:#2F92EE;'>#Venclyxto#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18374, encryptionId=c042183e4ad, topicName=Venclyxto)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=326b32021361, createdName=lifestar, createdTime=Mon Jan 25 13:48:28 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289094, encodeId=92e4128909463, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Fri Nov 13 13:48:28 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302348, encodeId=7b4113023486e, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Fri Nov 13 13:48:28 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391424, encodeId=e8af139142472, content=<a href='/topic/show?id=619a535491c' target=_blank style='color:#2F92EE;'>#慢性淋巴细胞性白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53549, encryptionId=619a535491c, topicName=慢性淋巴细胞性白血病)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epHkicC6GE1behbwHywld8qq5n70MWsL3lMUJYYzicic8Fh8tUgSDljeibIQrAeBicATBRXbcCRfFZGK6g/132, createdBy=1d8d2500080, createdName=ms5439512287675881, createdTime=Fri Nov 13 13:48:28 CST 2020, time=2020-11-13, status=1, ipAttribution=)]
    2020-11-13 wetgdt

    #淋巴细胞#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1805194, encodeId=a14118051942d, content=<a href='/topic/show?id=3138e790655' target=_blank style='color:#2F92EE;'>#细胞性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77906, encryptionId=3138e790655, topicName=细胞性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=86b7385, createdName=lqrandywkz, createdTime=Wed Feb 10 08:48:28 CST 2021, time=2021-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734273, encodeId=dc531e3427390, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Mon Jan 25 03:48:28 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715747, encodeId=7e191e1574717, content=<a href='/topic/show?id=c042183e4ad' target=_blank style='color:#2F92EE;'>#Venclyxto#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18374, encryptionId=c042183e4ad, topicName=Venclyxto)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=326b32021361, createdName=lifestar, createdTime=Mon Jan 25 13:48:28 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289094, encodeId=92e4128909463, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Fri Nov 13 13:48:28 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302348, encodeId=7b4113023486e, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Fri Nov 13 13:48:28 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391424, encodeId=e8af139142472, content=<a href='/topic/show?id=619a535491c' target=_blank style='color:#2F92EE;'>#慢性淋巴细胞性白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53549, encryptionId=619a535491c, topicName=慢性淋巴细胞性白血病)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epHkicC6GE1behbwHywld8qq5n70MWsL3lMUJYYzicic8Fh8tUgSDljeibIQrAeBicATBRXbcCRfFZGK6g/132, createdBy=1d8d2500080, createdName=ms5439512287675881, createdTime=Fri Nov 13 13:48:28 CST 2020, time=2020-11-13, status=1, ipAttribution=)]
    2020-11-13 ms5439512287675881

    #慢性淋巴细胞性白血病#

    0

相关资讯

Lancet oncol：维奈托克联合阿糖胞苷±伊达比星用于AML患儿的疗效和安全性

维奈托克联合化疗用于儿科重度复发性/难治性急性髓系白血病的安全性和疗效

2019年S​​OHO：Venetoclax联合Navitoclax治疗复发难治ALL和淋巴母细胞淋巴瘤前景光明

根据2019年血液肿瘤学会（S​​OHO）年会上发表的一项研究，将venetoclax和navitoclax与化学疗法相结合，可以为复发难治急性淋巴细胞白血病（ALL）或淋巴母细胞淋巴瘤患者带来希望。

Lancet Haematol：Venetoclax联合地西他滨10日疗法治疗各种AML亚型的疗效

地西他滨≥10天治疗方案已在2期临床试验中展现出了对高危AML患者的优越疗效。DiNardo等推测Venetoclax联合地西他滨10日疗法或可提高对新确诊的或复发性/难治性AML患者的疗效。

BCL-2抑制剂Venclexta（venetoclax）获得FDA全面批准：用以治疗急性髓细胞性白血病（AML）

近日，FDA已批准Venclexta（venetoclax）与阿扎胞苷、地西他滨或低剂量阿糖胞苷（LDAC）的组合，用于治疗75岁以上老年初治急性髓细胞性白血病（AML）患者。

NEJM：venetoclax联合ibrutinib一线治疗慢性淋巴细胞白血病

联合使用venetoclax和ibrutinib是治疗高风险和老年CLL患者的有效方案

Blood：决定AML老年患者经venetoclax联合化疗预后的分子特征！

中心点：适应性耐药可能是多克隆的，并与双等位基因TP53异常或激酶激活有关，特别是FLT3-ITD。NPM1突变与以venetoclax为基础的联合化疗后的良好的生存前景和持久的分子缓解相关。摘要：BCL-2抑制剂venetoclax联合低甲基化制剂或低剂量的阿糖孢苷是治疗老年或不适宜的急性髓系白血病（AML）患者的重要新疗法。DiNardo等人分析了81位采用以venetoclax为基础的联合化

拓展阅读

AJH：治疗和未治疗的慢性淋巴细胞白血病患者的第二原发恶性肿瘤发生率对比

之前CLL导向的治疗在血液学SPM的发展中发挥了作用，而它似乎并不影响大多数实体恶性肿瘤的发病率。

CD20单抗Ublituximab与PI3K抑制剂Umbralisib联合治疗慢性淋巴细胞白血病，获FDA快速通道指定

“很高兴获得ublituximab联合umbralisib（U2组合）治疗成人CLL的快速通道认证。这一称号将帮助加快U2的开发和监管审查。”

FDA授予Bcl-2抑制剂APG-2575孤儿药资格，用于治疗慢性淋巴细胞性白血病

慢性淋巴细胞性白血病（CLL）是一种成人白血病，其特征在于外周血、骨髓和淋巴组织中异常淋巴细胞的逐渐积累。根据美国癌症协会估计，到2020年，在美国每年约有4,060例死于该疾病。

Clin Cancer Res：CLL患者停用维奈克拉后，还可从BTK抑制中获益

Venetoclax(维奈克拉)是目前全球唯一获批上市的Bcl-2选择性抑制剂，用于治疗慢性淋巴细胞性白血病（CLL）或小淋巴细胞性淋巴瘤（SLL）。今年1月份，维奈克拉在国内申报上市。

**iPSC衍生的CAR-T细胞疗法：IND已获FDA批准

Fate Therapeutics是一家临床阶段的生物制药公司，致力于开发抗癌症和免疫疾病的细胞免疫疗法，今日宣布，美国FDA已批准FT819的研究性新药申请（IND）。

加拿大批准BCL-2抑制剂VENCLEXTA与CD20单抗Obinutuzumab联合，用于先前未治疗的慢性淋巴细胞性白血病患者

3期临床试验显示与接受obinutuzumab联合苯丁酸氮芥标准化疗方案的患者相比，VENCLEXTA联合obinutuzumab治疗患者的无进展生存期具有临床意义和统计学意义的改善。